iBET - Instituto de Biologia Experimental e Tecnológica
Category(ies): Contract Research Organisations; Public / Nonprofit Organisations; R&D Institutions
Address: Avenida da República, Quinta do Marquês, EAN, Apartado 12; 2781-901 Oeiras; Portugal
Keyword(s): Advanced Therapies, Biomedical engineering, Pharmaceuticals, Research & Development, Stem Cells Biotechnology
iBET is a private non-profit research intensive institution with over 25 years of experience in developing innovative solutions for the biopharmaceutical industry, SMEs, academic and private institutions. Key areas of expertise include the bioprocessing, production and in depth analysis of recombinant proteins and monoclonal antibodies, viral vaccines, viral vectors for gene therapy and stem cells for cell therapy applications; and in the development of in-vitro advanced cell models for pre-clinical research (eg. cancer, neural). iBET’s infrastructure comprises 16 cutting edge laboratories, a GMP certified Analytical Services Unit, a Pilot Plant for bioprocess development and production scale up and partners with the GMP manufacturer Genibet (45% owned by iBET, www.genibet.com) for production of biopharmaceutical for phase I/II clinical trials. IBET is also the coordinator of the “iNOVA4Health – Advancing Precision Medicine” Research Unit (www.inova4health.com), which organizes the efforts of biomedical researchers involved in biological understanding of disease, lead compounds and biopharmaceuticals “pre-discovery”, technological scientists involved in “preclinical development”, and clinicians involved in “early clinical and first in man clinical trials”. Trusting partners include international pharmaceutical companies, such as Bayer Healthcare, Novartis Pharma, Merck Serono, Abbvie, Sanoffi, Apceth, AstraZeneca, GSK, Merck & Co.